

## Pelvic floor dysfunction: prevention and non-surgical management Committee Meeting 5

**Date:** 9<sup>th</sup> March 2020

**Location:** RCOG, London

**Minutes:** Final

<b>Committee members present:</b>		
Raymond Jankowski (Chair)		Present for notes 1 – 7
Doreen McClurg (Topic Adviser)		Present for notes 1 – 7
Lucia Berry		Present for notes 1 – 7
Jennifer Davies		Present for notes 1 – 7
Lucy Dwyer		Present for notes 1 – 7
Mary McDonald		Present for notes 1 – 7
Julian Spinks		Present for notes 1 – 7
Phil Reed		Present for notes 1 – 7
Lucy Ryan		Present for notes 1 – 7
Ellie Stewart		Present for notes 1 - 7
Karen Ward		Present for notes 1 – 7
Priya Madhuvrata		Present for notes 5

<b>In attendance:</b>		
Katharina Dworzynski	NGA Guideline Lead	Present for notes 1 – 7
Patrice Carter	NGA Senior Systematic Reviewer	Present for notes 1 – 7
Jo Varley-Campbell	NGA Systematic Reviewer	Present for notes 1 – 7
Stephanie Armstrong	NGA Information Scientist	Present for notes 1 – 7
Clifford Middleton	NICE Guideline Commissioning Manager	Present for notes 1 – 7
Nicola Adanna Okeahialam	NGA Clinical Fellow	Present for notes 1 – 7

<b>Apologies:</b>	
Jim Khan	Committee member
Heather Boulton	Committee member

Catherine Heffernan	Committee member
Feima Ndoeka	NGA Project Manager
Paul Jacklin	NGA Health Economist
Steve Pilling	NGA Clinical Advisor
Elise Hasler	NGA Information Scientist

### 1. Welcome and objectives for the meeting

The Chair welcomed the committee members and attendees to the 5<sup>th</sup> meeting on Pelvic floor dysfunction: prevention and non-surgical management. The committee members and attendees introduced themselves.

The Chair informed the committee that apologies had been received as noted above.

The Chair outlined the objectives of the meeting, which included reviewing evidence and discussion of review protocols.

### 2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were pelvic floor dysfunction.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting. New interests were declared and noted below.

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Julian Spinks	Committee member	Direct financial	Lecture tour on nocturnal polyuria with speakers fees paid by Ferring Pharmaceuticals	27.02.2020	09.03.2020	12.03.2020	Declare and participate.  Rationale: This interest is non-specific

#### 4.0.03 DOC Cmte minutes

Ellie Stewart	Committee member	Non-financial professional and personal	Represented the RCN at a UTI POC symposium	24.02.2020	02.03.2020	24.02.2020	Declare and participate  Rationale: This declaration is non-specific to the scope.
Ellie Stewart	Committee member	Non-financial professional and personal	Written a book chapter about pelvic floor dysfunction, which is yet to be published		02.03.2020	Ongoing	Declare and participate  Rationale: This interest is relevant to the scope but it is background information rather than a specific opinion of how pelvic floor dysfunction should be managed.
Ellie Stewart	Committee member	Non-financial professional and personal	Study day teaching on point of contact development day	13.05.2020	02.03.2020	13.05.2020	Declare and participate  Rationale: This declaration is non-specific to the scope.

The Chair and Guideline Lead noted that the interests declared in the registry did not prevent the attendees from fully participating in the meeting.

### 3. Minutes of last meeting

The Chair asked the committee if it wanted any changes made to the minutes of the last meeting. The committee agreed that the minutes were a true and accurate account of the meeting.

The Chair confirmed that all matters arising had been completed or were in hand.

### 4. Morning presentations

The Chair introduced Nicola Adanna Okeahialam, NGA Clinical Fellow, who presented the evidence review for question 9.1 What is the effectiveness of physical devices (including support garments, pessaries and dilators) for improving symptoms of pelvic floor dysfunction?

The Chair introduced Stephanie Armstrong, Health Economist who presented the health economic evidence for question 9.1.

The Chair introduced Patrice Carter, Senior Systematic Reviewer, who presented the update on protocol 10.1 What is the effectiveness of psychological interventions for women with symptoms associated with pelvic floor dysfunction?

Patrice Carter also presented the protocol for question 12.1 What is the effectiveness of pharmacological management for improving?

### **5. Afternoon presentations**

The Chair introduced Jo Varley- Campbell, Systematic Reviewer, who presented the protocol for question 2.1 What are the non-obstetric risk factors (for example age, ethnicity and family history, diet [including caffeine and alcohol], weight, smoking, physical activity) for pelvic floor dysfunction?

### **6. Questions and discussions**

The committee discussed the evidence presented and made recommendations.

The committee discussed the protocols presented, made some amendments and signed them off.

### **7. Any other business**

No other business was raised.

**Date of next meeting:** 27<sup>th</sup> April 2020 (which had to be cancelled due to the pandemic)

**Location of next meeting:** RCOG, London